XPO1 and cancer: Blocking the nuclear export of proteins, particularly the cancer drug target topo IIα, can be achieved through three potential approaches: (1) CRM1 inhibitors, (2) NES small molecule inhibitors, and (3) casein kinase 2 inhibitors, with the last preventing post-translational phosphorylation of topo IIα.